Bimatoprost
Unchecked
Bimatoprost
Lumigan (glaucoma), Latisse (eyelash growth)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Primary open-angle glaucoma0, Ocular hypertension0, Eyelash hypotrichosis (Latisse)0
Pharmacy
Starting dose
1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime
Preparations
0.01%, 0.03% ophthalmic solution
US FDA Max
One drop per eye per day
Pharmacology
Routes
Topical ophthalmic
Onset
IOP lowering at 4 hours, maximum at 8-12 hours; eyelash effect after 2 months
Duration
24 hours
Half-life
~45 minutes (free acid in aqueous humor)[1]
Bioavailability
Topical; minimal systemic absorption[1]
Pregnancy
Limited data; weigh against alternatives.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Bimatoprost is a prostaglandin F2α analog (technically a prostamide) with potent agonism at the FP-receptor (prostaglandin F2α receptor); FP activation remodels the ciliary muscle extracellular matrix and increases uveoscleral aqueous outflow, lowering intraocular pressure by ~25-35%.0 Like latanoprost, characteristic adverse effects: iris pigmentation darkening (permanent), periocular pigmentation, eyelash growth (the off-label and now FDA-labeled cosmetic indication as Latisse), conjunctival hyperemia, periorbital fat atrophy (sunken upper sulcus, PAP — more pronounced than with latanoprost)[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Lumigan (bimatoprost), Allergan, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022184s007lbl.pdf